Cerulea Clinical Trials - Market Research Report

Company Overview

Cerulea Clinical Trials

Cerulea Clinical Trials is a not-for-profit ophthalmic clinical trials site that aims for a world free from vision loss and blindness. Their mission is to be a trusted partner in turning research discoveries into world market therapies by delivering excellence in ophthalmic clinical trials.

Mission: "Delivering excellence in ophthalmic clinical trials; Putting new therapies in sight."

Founded: No information is available

Founder: No information is available

Key People:

Michelle Gallaher, CEO

Professor Keith Martin, Cerulea Clinical Trials Chair, CERA Managing Director and University of Melbourne Professor and Head of Ophthalmology

Headquarters: Level 7, The Royal Victorian Eye and Ear Hospital, 32 Gisborne Street, East Melbourne 3002, VIC Australia

Number of Employees: No information is available

Revenue: No information is available

Known For: Specializes in ophthalmic clinical trials for biopharmaceutical and medtech companies, particularly in advanced therapeutics such as gene and cell therapies, biologics, and medical devices. Cerulea is also known for its collaboration with CERA (Centre for Eye Research Australia).

Products

Clinical Trials

Cerulea Clinical Trials offers a wide range of ophthalmic clinical trials for various eye conditions. These trials are conducted in collaboration with Australian and international biopharmaceutical and medtech companies as well as investigator-initiated studies for CERA and University of Melbourne’s Department of Surgery (Ophthalmology).

Product Description: Conducts Phase I-IV trials with specialist capabilities in glaucoma and retinal diseases, gene and cell therapies, and medical devices.

Key Features:

Phase I-IV Trials: Comprehensive trial phases for different stages of product development.

Specialist Capabilities: Focus areas include glaucoma, retinal diseases, gene and cell therapies, and medical devices.

Advanced Therapeutics: Trials include gene and cell therapies, biologics, and medical devices.

Expert Team: Experienced team committed to providing the best clinical trial experience for participants, clinicians, and sponsors.

State-of-the-art Facilities: Located within the Royal Victorian Eye and Ear Hospital with modern equipment and environments.

Recent Developments

New Centre and Partnerships

New Centre: On 17th September 2024, Cerulea Clinical Trials launched a new centre in Melbourne, aimed at bringing more international trials to Victoria and providing early access to sight-saving therapies. This state-of-the-art centre will focus on advanced therapeutics such as gene and cell therapies.

CEO Appointment: On 18th December 2023, Cerulea appointed Michelle Gallaher as the inaugural CEO. Michelle is a clinical trials innovator and digital health expert.

State-of-the-Art Clinical Trial Centre: As of 28th September 2023, Cerulea began work on a new clinical trial centre with advanced facilities designed to expand patient access and improve trial experiences.

$10M Funding: On 6th June 2023, Cerulea received a $10 million investment from Breakthrough Victoria to support the development of this cutting-edge centre.

New Trials and Research

Gene Therapies: New clinical trials focusing on gene therapies for retinitis pigmentosa and Stargardt’s disease are expected to begin in the next year.

Expanded Access: Plans to expand trial reach include a network of suburban and regional eye clinics and a tele-trials service to increase accessibility for participants.

Collaboration and Support

Partnerships: Cerulea collaborates extensively with pharmaceutical and medtech companies globally and is home to clinical research conducted by CERA scientists and University of Melbourne researchers.

Local Research Support: Ensures new eye treatments and devices developed in Australia are trialed locally, first benefiting Australian patients.

Community Support: The centre was built with the support of local investment and serves to strengthen Victoria's medical research sector.

Conclusion

Cerulea Clinical Trials stands out as a pioneering institution in the ophthalmic clinical trials field, leveraging cutting-edge research and advanced therapeutic methods to offer new treatments for vision-threatening conditions. With significant funding and support from local and international bodies, it continues to set new standards in eye health research and patient care.